BEAMSTART Logo

HomeNews

Patients Are Left With Few Options as GLP-1 Copycats Disappear

Wired LogoWired14h ago

Patients Are Left With Few Options as GLP-1 Copycats Disappear - Wired

Quick Summary:

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had come to rely on compounded versions is increasingly uncertain.

In the years these drugs have been in shortage, a cottage industry of telehealth companies and medical spas has sprung up offering compounded GLP-1 products for a fraction of the cost of the brand-name counterparts.

He’s unsure of what he’s going to do when he runs out later this month, and he is spending time scouring Reddit and Facebook forums to find which telehealth companies are still offering versions of the drugs.“Right now my plan is to take it month by month,” he says.“Hopping from provider to provider.


More Pictures

Patients Are Left With Few Options as GLP-1 Copycats Disappear - Wired (Picture 1)Patients Are Left With Few Options as GLP-1 Copycats Disappear - Wired (Picture 2)Patients Are Left With Few Options as GLP-1 Copycats Disappear - Wired (Picture 3)Patients Are Left With Few Options as GLP-1 Copycats Disappear - Wired (Picture 4)Patients Are Left With Few Options as GLP-1 Copycats Disappear - Wired (Picture 5)

or

Article Details

Author / Journalist: Emily Mullin, Kate Knibbs

Category: TechnologyEconomy

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-05-14 @ 10:30:00 (14 hours ago)

News Timezone: GMT +8:00

News Source URL: wired.com

Language: English

Article Length: 2564 words

Reading Time: 15 minutes read

Sentences: 101 lines

Sentence Length: 26 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Wired

News ID: 28708604

View Article Analysis

About Wired

Main Topics: TechnologyEconomy

Official Website: wired.com

Update Frequency: 5 posts per day

Year Established: 1993

Headquarters: United States

News Last Updated: 14 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #111

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Patients Are Left With Few Options as GLP-1 Copycats Disappear" has 2564 words across 101 sentences, which will take approximately 11 - 22 minutes for the average person to read.

Which news outlet covered this story?

The story "Patients Are Left With Few Options as GLP-1 Copycats Disappear" was covered 14 hours ago by Wired, a news publisher based in United States.

How trustworthy is 'Wired' news outlet?

Wired is a fully independent (privately-owned) news outlet established in 1993 that covers mostly technology and economy news.

The outlet is headquartered in United States and publishes an average of 5 news stories per day.

It's most recent story was published 14 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #28708604
  • URL: https://gaia.beamstart.com/news/patients-are-left-with-few-17472191217395

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2025 BEAMSTART. All Rights Reserved.